New analysis from the EARLY TAVR trial showed patients between the age of 65 and 70 years old derived the most benefits of a ...

New clinical results from multiple studies show coronary heart disease death associated with tobacco use is anticipated to rise up to 40% in the next five years and people with cannabis use disorder ...

For patients with asymptomatic or symptomatic carotid stenosis of 50 percent or greater with a low or intermediate predicted ...

Alembic Pharmaceuticals (Alembic) today announced that it has received final approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) Ticagrelor Tablets, ...

Alembic Pharmaceuticals announced that it has received final approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Ticagrelor Tablets, 90 mg, and ...

Patients hospitalized for heart failure who have cannabis use disorder (CUD) are significantly more likely to experience ...

The company on April 11 informed that it has received final approval from the United States Food and Drug Administration (USFDA) to manufacture Jaythari (Deflazacort) Tablets. Deflazacort is a ...

The following is a summary of "Sex differences in outcomes in patients with acute myocardial infarction," published in the ...

Febuxostat does not appear to increase the risk for major adverse cardiovascular events when compared with no urate-lowering ...

Anticoagulant drugs, whether classical ones such as warfarin and heparin or newer ones such as dabigatran and apixaban, can be effective for treating and preventing deep vein thrombosis, myocardial ...

In a recent study, one-year MACE incidences were 1.79, 2.58, and 4.03 per 100 patient-years for early, late, and no ezetimibe added to statins.

A potential strategy introduces an entirely new type of therapy capable of addressing previously ‘undruggable’ targets within ...